4.71
+1.07%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jacobio Pharmaceuticals Group Co
Its shares trade on HKEX under the ticker 1167.HK. It has been listed since 21 December 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥60.7m and a net loss of CN¥165.6m. At that date it held total assets of CN¥1.52bn and shareholders' equity of CN¥897.8m.
Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly conducts business within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Dec 2020
- Employees
- 300
- Website
- jacobiopharma.com ↗
Leadership
Pay as last reported
- Dr. Yinxiang WangExecutive Chairman of the Board, Chief Executive Officer, Founder, since 2018CN¥3.4m
- Ms. Yunyan HuExecutive Vice President, Executive Director, since 2018CN¥2.5m
- Ms. Xiaojie WangPresident of Administration, Executive Director, since 2015CN¥2.6m
- Dr. Andrea Wang-GillamChief Medical Officer, Global Head of Research and Development
- Mr. Ming Fai ChungJoint Company Secretary
- Ms. Qing XueJoint Company Secretary
- Dr. Te-Li ChenNon-Executive Director
- Dr. Bai LuNon-Executive Independent DirectorCN¥150,000
- Dr. Ruilin SongNon-Executive Independent DirectorCN¥400,000
- Dr. Ge WuNon-Executive Independent Director, since 2023CN¥200,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 95
- Environment
- 99
- Social
- 99
- Governance
- 86
- Direct emissions (scope 1)
- 43,077 t
- Energy emissions (scope 2)
- 252,636 t
- Women in the workforce
- 52%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jacobio Pharmaceuticals Group Co Ltd focuses on innovative tumor therapies with JAB-3068 and JAB-3312 clinical stage drugs.
- The company employs 300 full-time employees dedicated to biotechnology research and development.
- Jacobio's domestic market focus allows efficient resource allocation within China's Health Care sector.
Weaknesses
- Jacobio's business is limited to the domestic market, restricting international expansion opportunities.
- The company's primary drug development projects are still in clinical stages with no commercialized products.
- Jacobio has only 300 employees, which may limit its capacity for large-scale R&D initiatives.
Opportunities
- China's growing Health Care sector offers significant market potential for Jacobio's innovative therapies.
- The domestic market in China provides a stable environment for biotechnology research and development.
- JAB-3068 and JAB-3312 clinical stage drugs could attract investment as they progress through trials.
Threats
- Competition from established biotechnology firms in China's Health Care sector remains a challenge.
- Regulatory changes in China's biotechnology industry could impact drug development timelines.
- The clinical stage status of JAB-3068 and JAB-3312 poses risks of trial failures or delays.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.